Yes, Dravet is their lead program; like us, ADOA is their second program.
Their Dravet program is a year or so ahead of PYC’s lead program in RP11. But PYC looks like its third program will enter the clinic ahead of Stoke.
What is of interest is that when Stoke announced Phase1/2a results in late March, it doubled the share price. It’s traced back a bit since. Market cap is now ~A$912m.
Ann: Successful GLP Tox Studies in Second Blinding Eye Disease, page-8
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $816.5M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 17.0¢ | $224.4K | 1.287M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29999 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 772055 | 7 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |